TMCI — Treace Medical Concepts Share Price
0.000.00%
Last trade - 00:00- $735.80m
- $665.61m
- $187.12m
- 31
- 22
- 44
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.33 | ||
| Price to Tang. Book | 6.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.93 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.86% | ||
| Return on Equity | -49.91% | ||
| Operating Margin | -27.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 39.42 | 57.37 | 94.42 | 141.84 | 187.12 | 222.81 | 263.09 | 47.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.
Directors
- James Treace CHM (75)
- John Treace CEO (49)
- Mark Hair CFO (51)
- Daniel Owens CHO (49)
- Dipak Rajhansa SVP (51)
- Sean Scanlan SVP (39)
- Joe Ferguson SVP (52)
- Jaime Frias CCO (59)
- John Treace DRC (76)
- John Bakewell IND (60)
- F. Barry Bays IND (74)
- Lawrence Hamilton IND (63)
- Betsy Hanna IND
- Deepti Jain IND (53)
- Richard Mott IND (61)
- Thomas Timbie IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 13th, 2014
- Public Since
- April 23rd, 2021
- No. of Shareholders
- 24
- No. of Employees
- 516
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 61,936,000
- Address
- 100 Palmetto Park Place, PONTE VEDRA, 32081
- Web
- https://www.treace.com/
- Phone
- +1 9043735940
- Contact
- Lynn Lewis
- Auditors
- Grant Thornton LLP
Upcoming Events for TMCI
Q1 2024 Treace Medical Concepts Inc Earnings Call
Treace Medical Concepts Inc Annual Shareholders Meeting
Treace Medical Concepts Inc Annual Shareholders Meeting
Q2 2024 Treace Medical Concepts Inc Earnings Release
Similar to TMCI
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Treace Medical Concepts share price?
As of Today at 19:22 UTC, shares in Treace Medical Concepts are trading at $11.88. This share price information is delayed by 15 minutes.
How has the Treace Medical Concepts share price performed this year?
Shares in Treace Medical Concepts last closed at $11.88 and the price had moved by -54.18% over the past 365 days. In terms of relative price strength the Treace Medical Concepts share price has underperformed the S&P500 Index by -63% over the past year.
What are the analyst and broker recommendations for Treace Medical Concepts?
The overall consensus recommendation for Treace Medical Concepts is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Treace Medical Concepts dividend yield?
Treace Medical Concepts does not currently pay a dividend.
Does Treace Medical Concepts pay a dividend?
Treace Medical Concepts does not currently pay a dividend.
When does Treace Medical Concepts next pay dividends?
Treace Medical Concepts does not currently pay a dividend.
How do I buy Treace Medical Concepts shares?
To buy shares in Treace Medical Concepts you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Treace Medical Concepts?
As of the previous close price of $11.88, shares in Treace Medical Concepts had a market capitalisation of $735.80m.
Where are Treace Medical Concepts shares listed?
Here are the trading details for Treace Medical Concepts:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TMCI
What kind of share is Treace Medical Concepts?
Based on an overall assessment of its quality, value and momentum Treace Medical Concepts is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Treace Medical Concepts share price forecast for 2024?
The analyst consensus target price for shares in Treace Medical Concepts is $15.86. That is 33.5% above the last closing price of $11.88.
Analysts covering Treace Medical Concepts currently have a consensus Earnings Per Share (EPS) forecast of -$0.93 for the next financial year.
What is the trend in the Treace Medical Concepts share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Treace Medical Concepts. Over the past six months, its share price has outperformed the S&P500 Index by +0.31%.
As of the last closing price of $11.88, shares in Treace Medical Concepts were trading -15.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Treace Medical Concepts PE Ratio?
The Treace Medical Concepts PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Treace Medical Concepts?
Treace Medical Concepts' management team is headed by:
- James Treace - CHM
- John Treace - CEO
- Mark Hair - CFO
- Daniel Owens - CHO
- Dipak Rajhansa - SVP
- Sean Scanlan - SVP
- Joe Ferguson - SVP
- Jaime Frias - CCO
- John Treace - DRC
- John Bakewell - IND
- F. Barry Bays - IND
- Lawrence Hamilton - IND
- Betsy Hanna - IND
- Deepti Jain - IND
- Richard Mott - IND
- Thomas Timbie - IND